Research Reports | Market Assessment
April 2016

Dyslipidemia | Current Treatment | US | 2016

Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease, but the impact on CV risk varies by lipid disorder. Treatment has centered mainly on reducing the levels of atherogenic lipids, but physicians are increasingly seeking evidence of CV outcomes benefits. Numerous treatments are available, but few have solid evidence of CV benefit, and therapeutic approaches can vary. The recent launches of the novel proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, which are expected to deliver clinically meaningful improvements in outcomes, will reshape the current treatment paradigm.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports